<p>(<b>A</b>) B6 mice were primed, or primed and boosted intradermally with 5×10<sup>6</sup> TU of Lv-OVA/Luc, and luciferase expression was determined <i>in vivo</i> using whole body imagining. The mean relative light unit (RLU) values expressed by a group of 4 mice ± SE are presented. (<b>B</b>) Immunization site of Lv-OVA (5×10<sup>6</sup> TU) homologously boosted mice was removed on days 2, 4 or 6 following immunization, and the magnitude of OVA-specific CD8<sup>+</sup> T cells was analyzed. Data are showed as the mean percentage ± SE of CD8<sup>+</sup> tetramer<sup>+</sup> T cells. n = 3 mice per group for each time point. (<b>C</b>) Mice were primed with Lv-OVA and 7 weeks later were boosted with Lv-OVA (Lv-Lv) or Ad-OVA (Lv-Ad). In ...
<p>Mice immunized with OVA +/− HLT adjuvants were challenged with 5×10<sup>6</sup> CFU of recombinan...
<p>WT or <i>Hvem</i><sup>−/−</sup> mice were orally infected with 1×10<sup>9</sup> LM-OVA and the am...
<p>C57BL/6 mice were treated twice with 250 µg anti-CD4 Ab (GK1.5 Harlan) two and one day prior to i...
<p>B6 mice were primed, or primed and boosted with Lv-OVA, and then were adoptively transferred i.v....
<p>A- WT and <i>Btla</i><sup>−/−</sup> mice were orally infected with 1×10<sup>9</sup> LM-OVA and 7 ...
<p>Mice were primed with DNA and boosted with Ad5-NS3/4A (Ad5) (10<sup>9</sup> vp), VV-NS3/4A (VV) (...
<p>Mice were immunized with different recombinant MVAs expressing ovalbumin (OVA) under the control ...
<p>C57BL/6J (WT) and FtDKO mice were immunized intravenously with 10<sup>4</sup> LM-OVA. Representat...
<p><b>(A)</b> The magnitude of the CD8<sup>+</sup> T cell responses specific to the indicated epitop...
<p>(<b>A</b>) B6 or SM-Ova mice were immunized with rAAV-Ova, replicative VSV-Ova or live Lm-Ova. Se...
<p>C57BL/6 mice were challenged with E.G7 and then, 7 days post tumor challenge, were treated as ind...
<p>Mice primed with Lm-OVA were boosted 21 days later with the indicated dose of Lm-OVA. 5 days post...
<p>(A) A representative flow cytometry analysis performed in a tetramer assay. Tetramer positive OVA...
<p>Analysis of CD8<sup>+</sup> T cell responses in spleens from WT (in white) and GITRL tg (in black...
<p><b>(A)</b> Design of vaccine-challenge studies. Mice received footpad immunizations on Days 0 and...
<p>Mice immunized with OVA +/− HLT adjuvants were challenged with 5×10<sup>6</sup> CFU of recombinan...
<p>WT or <i>Hvem</i><sup>−/−</sup> mice were orally infected with 1×10<sup>9</sup> LM-OVA and the am...
<p>C57BL/6 mice were treated twice with 250 µg anti-CD4 Ab (GK1.5 Harlan) two and one day prior to i...
<p>B6 mice were primed, or primed and boosted with Lv-OVA, and then were adoptively transferred i.v....
<p>A- WT and <i>Btla</i><sup>−/−</sup> mice were orally infected with 1×10<sup>9</sup> LM-OVA and 7 ...
<p>Mice were primed with DNA and boosted with Ad5-NS3/4A (Ad5) (10<sup>9</sup> vp), VV-NS3/4A (VV) (...
<p>Mice were immunized with different recombinant MVAs expressing ovalbumin (OVA) under the control ...
<p>C57BL/6J (WT) and FtDKO mice were immunized intravenously with 10<sup>4</sup> LM-OVA. Representat...
<p><b>(A)</b> The magnitude of the CD8<sup>+</sup> T cell responses specific to the indicated epitop...
<p>(<b>A</b>) B6 or SM-Ova mice were immunized with rAAV-Ova, replicative VSV-Ova or live Lm-Ova. Se...
<p>C57BL/6 mice were challenged with E.G7 and then, 7 days post tumor challenge, were treated as ind...
<p>Mice primed with Lm-OVA were boosted 21 days later with the indicated dose of Lm-OVA. 5 days post...
<p>(A) A representative flow cytometry analysis performed in a tetramer assay. Tetramer positive OVA...
<p>Analysis of CD8<sup>+</sup> T cell responses in spleens from WT (in white) and GITRL tg (in black...
<p><b>(A)</b> Design of vaccine-challenge studies. Mice received footpad immunizations on Days 0 and...
<p>Mice immunized with OVA +/− HLT adjuvants were challenged with 5×10<sup>6</sup> CFU of recombinan...
<p>WT or <i>Hvem</i><sup>−/−</sup> mice were orally infected with 1×10<sup>9</sup> LM-OVA and the am...
<p>C57BL/6 mice were treated twice with 250 µg anti-CD4 Ab (GK1.5 Harlan) two and one day prior to i...